Missing Electronic Signature Policy: A Risk to Data Integrity and GMP Compliance

Introduction to the Audit Finding

1. Undefined e-Signature Protocols

Organizations lack written procedures governing electronic signatures used in GMP operations.

2. Violation of 21 CFR Part 11

Absence of a policy for electronic records and signatures violates FDA expectations for system compliance.

3. Data Authenticity Risk

Without a defined policy, there’s no assurance that signatures are attributable, legible, and secure.

4. Access and Authorization Gaps

No rules defined for who can sign electronically, under what conditions, and how audit trails are retained.

5. Frequent FDA Audit Finding

Not having a formal policy for e-signature use is often cited as a critical observation in data integrity audits.

6. Impact on Traceability

Lack of e-signature protocols compromises ALCOA+ principles and traceability of GMP records.

7. Internal Misuse Potential

In absence of proper controls, shared login use or ghost approvals may occur without accountability.

8. Link to Stability indicating methods

Electronic data in stability systems must be signed off as per validated e-signature protocols.

Regulatory Expectations and Inspection Observations

1. 21 CFR Part 11

Requires electronic signatures to be unique, verifiable, and equivalent to handwritten signatures.

2. EU GMP Annex 11

Mandates clear policies for electronic signatures and audit trail protection in computerized systems.

3. WHO Annex 5

States electronic signatures must be supported by access controls, system validation, and SOPs.

4. FDA 483 Language

“Your system does not include adequate controls to ensure the authenticity of electronic signatures used to approve GMP records.”

5. MHRA Expectations

GMP systems must demonstrate electronic signatures are protected, unique, and restricted to authorized users.

6. CDSCO Guidelines

Encourages alignment with global expectations under 21 CFR Part 11 and EU GMP for electronic records.

7. Health Canada Compliance

Requires evidence that electronic signature systems are validated and governed by SOPs.

8. USFDA Enforcement

Enforces citations under Part 11 for absence or misuse of electronic signatures in regulated activities.

Root Causes of Electronic Signature Policy Absence

1. Lack of IT-QA Collaboration

IT implements systems, but QA is not involved in drafting or reviewing e-signature policies.

2. No SOP Template for e-Signatures

The SOP framework doesn’t include guidance or structure for e-signature governance.

3. Unvalidated Systems

Electronic systems used are not Part 11 compliant or have not undergone formal validation.

4. Incomplete Understanding of Part 11

Personnel are unaware of the regulatory obligations related to electronic records and signatures.

5. No Risk-Based Assessment

Systems are not assessed for their GxP criticality or data integrity impact before use.

6. Focus on Paper Records

Organizations still rely heavily on paper-based workflows and ignore digital compliance needs.

7. Shared Logins

Multiple users access systems with common credentials, compromising identity verification.

8. Absence of Audit Trails

Systems lack or do not enforce audit trail capture of signature events and approvals.

Prevention of Policy Gaps in Electronic Signatures

1. Draft e-Signature SOP

Create an SOP defining acceptable use, formats, identity checks, and validation requirements.

2. Implement Role-Based Access

Limit e-signature privileges only to trained and authorized personnel.

3. Validate Part 11 Systems

Ensure computerized systems used for GMP records meet all technical and procedural Part 11 controls.

4. Audit Trail Review SOP

Define how electronic approvals and audit trails are periodically reviewed by QA.

5. Prohibit Shared Credentials

System settings must enforce unique usernames and disable shared login usage.

6. QA Oversight

Quality Assurance should control and approve system configuration related to e-signatures.

7. Mandatory IT-QA SOP Alignment

All IT system procedures should be reviewed by QA for regulatory compliance prior to implementation.

8. Update Training Programs

Include electronic signature usage and policy awareness in GMP and data integrity training.

Corrective and Preventive Actions (CAPA)

1. Draft and Approve SOP

Develop a comprehensive SOP on the use of electronic signatures including roles, conditions, and validation.

2. Conduct Risk Assessment

Identify systems using e-signatures and evaluate risks to data integrity and compliance.

3. Restrict Access Rights

Review all system roles and restrict signature functionality to trained, authorized users only.

4. Initiate System Validation

Validate systems according to 21 CFR Part 11 and EU Annex 11 requirements including audit trail checks.

5. Train All System Users

Conduct mandatory training on new e-signature policy and verification steps for approval actions.

6. Link e-Signature Use to Change Control

Ensure that all changes requiring signatures are traceable via electronic approval records.

7. Include e-Signature Checks in QA Review

QA must verify correct and compliant usage of e-signatures during batch record and deviation reviews.

8. Internal Audit Inclusion

Add electronic signature usage and audit trail review into the internal audit checklist for all applicable systems.